Investors Hangout Stock Message Boards Logo
  • Home
  • Mailbox
  • Boards
  • Favorites
  • Whats Hot!
  • Login - Join Now!
Profile
ohm20's Profile
Displaying 1701-1750 of 6028 result(s).
CYDY CytoDyn Inc
02/22/2022 10:57:59 AM
Remdesivir's MOA is based on disrup (10)
CYDY CytoDyn Inc
02/22/2022 9:59:29 AM
My point in that post was that no e (3)
CYDY CytoDyn Inc
02/22/2022 4:17:21 AM
The Pfizer trial is using the Natio (9)
CYDY CytoDyn Inc
02/22/2022 2:17:20 AM
In this setting, causation would li (5)
CYDY CytoDyn Inc
02/22/2022 2:10:55 AM
and why would we devise a protocol (5)
CYDY CytoDyn Inc
02/20/2022 10:39:12 AM
An answer to a post that has been d (21)
CYDY CytoDyn Inc
02/19/2022 11:07:07 PM
The CCR5 receptor is directly impli (4)
CYDY CytoDyn Inc
02/19/2022 11:02:06 PM
In Alzheimer's there was no treatme (4)
CYDY CytoDyn Inc
02/19/2022 10:50:09 PM
I think the deal was we were only s (6)
CYDY CytoDyn Inc
02/19/2022 10:39:04 PM
HIV is already committed to the she (4)
CYDY CytoDyn Inc
02/19/2022 10:31:23 PM
I will add that Ohm stated the prob (2)
CYDY CytoDyn Inc
02/19/2022 10:23:54 PM
Isn’t it correct that after Trode (3)
CYDY CytoDyn Inc
02/19/2022 2:02:49 PM
A 200 patient phase 2 would have me
CYDY CytoDyn Inc
02/19/2022 1:15:21 PM
Unless I am totally wrong and you c (2)
CYDY CytoDyn Inc
02/18/2022 10:43:32 PM
You may count unexercisable warrant
CYDY CytoDyn Inc
02/18/2022 10:10:07 PM
Go up to the offices dressed as a D (14)
CYDY CytoDyn Inc
02/18/2022 9:30:53 PM
RTB's starting point of 176.4 milli (2)
CYDY CytoDyn Inc
02/18/2022 9:09:55 PM
I was paying a little attention to
CYDY CytoDyn Inc
02/18/2022 6:16:14 PM
That he prides himself on having hi (3)
CYDY CytoDyn Inc
02/18/2022 5:41:54 PM
I started with the number in the 10 (2)
CYDY CytoDyn Inc
02/18/2022 5:36:16 PM
I just finished going through it. I (16)
CYDY CytoDyn Inc
02/18/2022 3:49:05 PM
That was from RTB I believe. I thin
CYDY CytoDyn Inc
02/18/2022 3:46:38 PM
Without drearily wading through the (1)
CYDY CytoDyn Inc
02/18/2022 2:46:53 PM
This discussion of Cytolin has me w (8)
CYDY CytoDyn Inc
02/18/2022 2:12:54 PM
It is true and yet amusing. (2)
CYDY CytoDyn Inc
02/18/2022 1:19:15 PM
Before Nader they had a failed HIV (2)
CYDY CytoDyn Inc
02/18/2022 6:22:51 AM
Exactly - https://investorshangout. (1)
CYDY CytoDyn Inc
02/18/2022 3:28:25 AM
I will soon be making a response to (14)
CYDY CytoDyn Inc
02/18/2022 3:20:50 AM
The deal will have predated his ass
CYDY CytoDyn Inc
02/18/2022 2:52:51 AM
The Fife deal was for convertible n (3)
CYDY CytoDyn Inc
02/18/2022 12:54:29 AM
I just took a look at the biopharma (7)
CYDY CytoDyn Inc
02/17/2022 11:42:11 PM
And now I would like to know how it (2)
CYDY CytoDyn Inc
02/17/2022 11:23:12 PM
What is happening?!?!?!?¿ This isn (11)
CYDY CytoDyn Inc
02/17/2022 10:12:28 PM
A detailed breakdown of our NASH 70 (6)
CYDY CytoDyn Inc
02/17/2022 8:28:21 PM
We still have plenty of shares. Wha (4)
CYDY CytoDyn Inc
02/17/2022 8:11:36 PM
Will we see David Welch as member o (5)
CYDY CytoDyn Inc
02/17/2022 6:39:37 PM
Correction, yes it is David F. Welc (3)
CYDY CytoDyn Inc
02/17/2022 6:14:47 PM
No, It's David F. Welch.
CYDY CytoDyn Inc
02/17/2022 6:13:13 PM
I only took a very quick look at th (4)
CYDY CytoDyn Inc
02/17/2022 5:53:22 PM
In the middle of a buyout scenario (1)
CYDY CytoDyn Inc
02/17/2022 5:47:46 PM
My mistake substitute Dark energy f (1)
CYDY CytoDyn Inc
02/17/2022 5:37:55 PM
The payment obligations of the Comp (2)
CYDY CytoDyn Inc
02/17/2022 5:32:53 PM
including inverting the sign of the
CYDY CytoDyn Inc
02/17/2022 5:30:37 PM
I'll give you my take when the enti (1)
CYDY CytoDyn Inc
02/17/2022 5:18:28 PM
Make sure to get in on the IPO then (2)
CYDY CytoDyn Inc
02/17/2022 4:57:06 PM
What was said before and after that (2)
CYDY CytoDyn Inc
02/17/2022 4:52:06 PM
Even on the off chance it did work (1)
CYDY CytoDyn Inc
02/17/2022 4:27:51 PM
I wish I would have pulled the trig (5)
CYDY CytoDyn Inc
02/17/2022 2:18:33 PM
I think the money from Pharma that (8)
CYDY CytoDyn Inc
02/17/2022 2:14:24 PM
Chlorine dioxide in very small dose (3)
Go to page:
  • << First
  • < Previous
  • 34
  • 35
  • Next >

Recent Articles

  • Strata Critical Medical Announces Business Transition and Growth Plans
  • SaverOne Achieves Significant Milestones and Growth in 2025
  • Global Water Resources Announces Monthly Cash Dividend Update
  • Hawkins, Inc. Strengthens Market with StillWaters Acquisition
  • Esperion's Bempedoic Acid Achieves Major Regulatory Milestone
  • Strategic Partnership between Connexa Sports and JuCoin for aiRWA
  • Rocket Doctor AI Achieves First Revenue Milestone Post-Acquisition
  • Rio2 Limited Secures TSX Listing: A New Era Begins
  • Applied Digital Expands AI Infrastructure with New Lease Agreement
  • Tatu Kaleva's Recent Stock Acquisitions at Verkkokauppa.com
  • SAIC's Board Declares Cash Dividend and Future Intentions
  • Frontline plc's Comprehensive Overview for Second Quarter Results
  • SAIC Board Announces Quarterly Cash Dividend for Stockholders
  • Strength and Stability in the Market: Amphenol and EMCOR Analysis
  • Top Investment Picks on CNBC: Insights and Trends Revealed
  • SHARC Energy's Q2 2025 Results Showcase Strong Growth Potential
  • QYOU Media's Strategic Shift: A Positive Outlook for Future Growth
  • Understanding Patent Strategies: Insights from Orexo's Success
  • Metavesco Plans Major Live Announcement for OTC Community Impact
  • Exploring Orexo's Pharmaceutical Innovations and IP Strategies
  • The Home Depot Secures Approval for GMS Inc. Acquisition
  • Columbia Banking System to Announce Q3 2025 Financial Results
  • QYOU Media Achieves Positive EBITDA: Insights into Growth
  • Blum Holdings Inc. Transitions to Growth in 2025 Executive Summary
  • Vaxart's Nasdaq Compliance Extension: Future Opportunities Ahead
  • Cryptocurrency Market Update: Major Coins Face Declines
  • DeFi Development Corp. Unveils First UK Solana Treasury Vehicle
  • Replimune Group Faces Class Action Lawsuit for Misconduct
  • SHARC Energy's Exciting Growth and Financial Progress in 2025
  • CG Oncology's Leaders Set for Key Investor Events Ahead
  • Praxis Precision Medicines to Engage in Insightful Discussion
  • Praxis Precision Medicines CEO to Join Virtual Fireside Chat
  • Plumas Bank's 2025 Report: Strengthening Growth and Inclusion
  • Avadel Pharmaceuticals Highlights Upcoming Investor Events
  • CG Oncology Leadership Engages Investors at Key Conferences
  • Exciting Updates from Avadel Pharmaceuticals on Future Conferences
  • Applied Digital Strengthens AI Infrastructure with New Lease
  • Gauzy Secures Exclusive Partnership with Major U.S. Financial Firm
  • A Transformative Leadership Approach: Embracing Empathy
  • Emergent BioSolutions Launches Naloxone Education for Students
  • America’s Car-Mart Achieves Milestone with $172M Securitization
  • Emergent BioSolutions Promotes Naloxone Awareness for Students
  • Rio2 Limited Achieves Major Milestone with TSX Listing
  • Celsius Captures PepsiCo's Energy Drink Strategy in New Alliance
  • Exploring Orexo's Patent Strategies and Legal Triumphs in Pharma
  • Metavesco Set to Unveil Game-Changing News for Investors
  • Challenges Ahead for Frontline: Market Volatility and Tensions
  • Groundbreaking $951 Million Verdict in Hospital Malpractice Case
  • Fosun International's Vision for Global Leadership in Pharma
  • Fosun's Strategic Innovations Aim for Global Leadership in Pharma
  • Home - Investors HangoutHome

  • Mailbox - Investors HangoutMailbox

  • Boards - Investors HangoutBoards

  • Favorites - Investors HangoutFavorites

  • Whats Hot! - Investors HangoutWhats Hot!

  • More - Investors HangoutMore

  • Settings - Investors HangoutSettings
  • Login - Investors HangoutLogin
  • Live Site - Investors HangoutLive Site